The breakthrough behind orexin agonist drugs, a potential successor to GLP-1s, came from studying narcolepsy in dogs. A Stanford researcher identified a genetic mutation in Dobermans and Labradors that prevented them from responding to the orexin molecule, directly linking it to wakefulness and creating a path for new human therapies.

During deep slow-wave sleep, neurons synchronize their firing, causing them to physically expand and contract in unison. This collective movement acts like a 'bilge pump,' actively flushing out metabolic debris and misfolded proteins from the brain. This cleanup is essential for next-day cognitive function and is concentrated in the first third of the night.

While diet and exercise are often cited, neurobiologist Al Sandrock emphasizes sleep for Alzheimer's prevention. The brain has a natural clearance system that removes amyloid protein—a key culprit in the disease—during sleep. Therefore, consistently getting good sleep is a critical lifestyle intervention.

Unlike sedatives, DORA-class sleep aids (Dual Orexin Receptor Antagonists) work by inhibiting wakefulness, creating more natural sleep architecture. Research suggests this may improve the brain's ability to clear beta-amyloid and tau proteins linked to Alzheimer's disease, offering a potential preventative strategy.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Unlike sedatives like Ambien, a new class of medication (DORAs) works by dialing down the brain's wakefulness chemical (orexin). This allows for naturalistic sleep that is functionally beneficial, proven to increase the brain's cleansing of beta amyloid and tau protein, which are linked to Alzheimer's disease.

Amyloid beta, often demonized as a toxic waste product in Alzheimer's, is fundamentally an antimicrobial peptide that protects brain cells. The problem arises not from its existence, but from the brain's inability to clear it effectively during sleep, leading to harmful accumulation.

The speaker positions NKEVs not as a monotherapy but as a foundational treatment. A key hypothesis is that by clearing amyloid from the brain's vasculature, NKEVs could mitigate the brain bleeding (ARIA) side effects that have plagued anti-amyloid antibody therapies. This would make combination treatments both safer and more effective.